In Friday’s Wall Street session, Jade Biosciences Inc (NASDAQ:JBIO) shares traded at $7.03, down -3.96% from the previous session.
JBIO stock price is now -23.57% away from the 50-day moving average and -19.07% away from the 200-day moving average. The market capitalization of the company currently stands at $6.47M.
With the price target of $17, Wedbush recently initiated with Outperform rating for Jade Biosciences Inc (NASDAQ: JBIO). On May 05, 2025, Stifel recently initiated its ‘Buy’ rating on the stock quoting a target price of $19, while ‘TD Cowen’ rates the stock as ‘Buy’
In other news, Frohlich Tom, Chief Executive Officer bought 6,000 shares of the company’s stock on May 16 ’25. The stock was bought for $44,400 at an average price of $7.40. Upon completion of the transaction, the Chief Executive Officer now directly owns 6,000 shares in the company, valued at $42180.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 06 ’25, Shareholder Atlas Venture Associates XII, bought 48 shares of the business’s stock. A total of $552 was incurred on buying the stock at an average price of $11.50. A total of 18.02% of the company’s stock is owned by insiders.
During the past 12 months, Jade Biosciences Inc has had a low of $4.57 and a high of $92.46. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 32.01, and a quick ratio of 32.01. The fifty day moving average price for JBIO is $59.3906 and a two-hundred day moving average price translates $75.98128 for the stock.
The latest earnings results from Jade Biosciences Inc (NASDAQ: JBIO) was released for 2025-03-31.
